




RealRate

PHARMACEUTICAL 2017

International Stem Cell CORP
Rank 141 of 292





RealRate

PHARMACEUTICAL 2017

International Stem Cell CORP Rank 141 of 292



The relative strengths and weaknesses of International Stem Cell CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of International Stem Cell CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 132% points. The greatest weakness of International Stem Cell CORP is the variable Assets, Current, reducing the Economic Capital Ratio by 107% points.

The company's Economic Capital Ratio, given in the ranking table, is 91%, being 88% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	2,492
Cost of Goods Sold	1,944
Intangible Assets	3,484
Liabilities, Current	3,601
Liabilities, Non-Current	0
Other Assets	673
Other Compr. Net Income	0
Other Expenses	2,527
Other Liabilities	0
Other Net Income	3,772
Other Revenues	7,165
Property and Equipment	396
Research and Development	2,856
Selling, General and Administrative Expense	4,689

Output Variable	Value in 1000 USD
Assets	7,045
Liabilities	3,601
Expenses	12,016
Revenues	7,165
Stockholders Equity	3,444
Net Income	-1,079
Comprehensive Net Income	-1,079
Economic Capital Ratio	91%